|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
1998-9-16
|
|
pubmed:abstractText |
Pirfenidone (PFD) is a novel anti-fibrotic agent that can prevent and even reverse extracellular matrix accumulation in several organs, as shown by experimental and clinical studies. Unilateral ureteral obstruction (UUO) is a well-characterized model of experimental renal disease culminating in tubulointerstitial fibrosis.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Anti-Inflammatory Agents...,
http://linkedlifedata.com/resource/pubmed/chemical/Collagen,
http://linkedlifedata.com/resource/pubmed/chemical/Gelatinases,
http://linkedlifedata.com/resource/pubmed/chemical/Hydroxyproline,
http://linkedlifedata.com/resource/pubmed/chemical/Inulin,
http://linkedlifedata.com/resource/pubmed/chemical/Matrix Metalloproteinase 2,
http://linkedlifedata.com/resource/pubmed/chemical/Metalloendopeptidases,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridones,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Messenger,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Ribosomal, 18S,
http://linkedlifedata.com/resource/pubmed/chemical/RNA, Ribosomal, 28S,
http://linkedlifedata.com/resource/pubmed/chemical/Transforming Growth Factor beta,
http://linkedlifedata.com/resource/pubmed/chemical/pirfenidone
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0085-2538
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
54
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
99-109
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:9648068-Administration, Oral,
pubmed-meshheading:9648068-Animals,
pubmed-meshheading:9648068-Anti-Inflammatory Agents, Non-Steroidal,
pubmed-meshheading:9648068-Body Weight,
pubmed-meshheading:9648068-Collagen,
pubmed-meshheading:9648068-Disease Models, Animal,
pubmed-meshheading:9648068-Fibrosis,
pubmed-meshheading:9648068-Gelatinases,
pubmed-meshheading:9648068-Hydroxyproline,
pubmed-meshheading:9648068-Inulin,
pubmed-meshheading:9648068-Kidney Cortex,
pubmed-meshheading:9648068-Kidney Function Tests,
pubmed-meshheading:9648068-Ligation,
pubmed-meshheading:9648068-Male,
pubmed-meshheading:9648068-Matrix Metalloproteinase 2,
pubmed-meshheading:9648068-Metalloendopeptidases,
pubmed-meshheading:9648068-Pyridones,
pubmed-meshheading:9648068-RNA, Messenger,
pubmed-meshheading:9648068-RNA, Ribosomal, 18S,
pubmed-meshheading:9648068-RNA, Ribosomal, 28S,
pubmed-meshheading:9648068-Rats,
pubmed-meshheading:9648068-Rats, Sprague-Dawley,
pubmed-meshheading:9648068-Transforming Growth Factor beta,
pubmed-meshheading:9648068-Ureter,
pubmed-meshheading:9648068-Ureteral Obstruction
|
|
pubmed:year |
1998
|
|
pubmed:articleTitle |
Pirfenidone improves renal function and fibrosis in the post-obstructed kidney.
|
|
pubmed:affiliation |
Shionogi Research Laboratories, Osaka, Japan. toshikatsu.shimizu@shionogi. co.jp
|
|
pubmed:publicationType |
Journal Article
|
